• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

    2/13/23 4:20:35 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MACK alert in real time by email
    SC 13G/A 1 sc13ga310680mack_02132023.htm AMENDMENT NO. 3 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 3)1

     

    Merrimack Pharmaceuticals, Inc.

     (Name of Issuer)

    Common Stock, par value $0.01 per share

     (Title of Class of Securities)

    590328209

     (CUSIP Number)

    December 31, 2022

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 590328209

     

      1   NAME OF REPORTING PERSON  
             
            22NW Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,015,048  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,015,048  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,015,048  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 590328209

      1   NAME OF REPORTING PERSON  
             
            22NW, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,015,048  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,015,048  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,015,048  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    3

    CUSIP No. 590328209

     

      1   NAME OF REPORTING PERSON  
             
            22NW Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,015,048  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,015,048  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,015,048  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.6%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    4

    CUSIP No. 590328209

     

      1   NAME OF REPORTING PERSON  
             
            22NW GP, Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,015,048  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,015,048  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,015,048  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.6%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    5

    CUSIP No. 590328209

     

      1   NAME OF REPORTING PERSON  
             
            Aron R. English  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,015,048  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,015,048  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,015,048  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.6%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    6

    CUSIP No. 590328209

     

    Item 1(a).Name of Issuer:

     

    Merrimack Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    One Broadway, 14th Floor

    Cambridge, MA 02142

     

    Item 2(a).Name of Person Filing:

     

    This statement is filed by 22NW Fund, LP, a Delaware limited partnership (“22NW Fund”), 22NW, LP, a Delaware limited partnership (“22NW”), 22NW Fund GP, LLC, a Delaware limited liability company (“22NW GP”), 22NW GP, Inc., a Delaware S Corporation (“22NW Inc.”), and Aron R. English. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    22NW serves as the investment manager of 22NW Fund. 22NW GP serves as the general partner of 22NW Fund. 22NW Inc. serves as the general partner of 22NW. Mr. English is the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc. By virtue of these relationships, 22NW, 22NW GP, 22NW Inc. and Mr. English may be deemed to beneficially own the Shares (as defined below) owned directly by 22NW Fund.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal office of each of the Reporting Persons is 1455 NW Leary Way, Suite 400, Seattle, Washington 98107.

     

    Item 2(c).Citizenship:

     

    22NW Fund, 22NW, 22NW GP and 22NW Inc. are organized under the laws of the State of Delaware. Mr. English is a citizen of the United States of America.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.01 par value per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    590328209

    7

    CUSIP No. 590328209

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    As of the close of business on December 31, 2022:

     

    (i)22NW Fund directly owned 1,015,048 Shares.

     

    (ii)Each of 22NW, as the investment manager of 22NW Fund, 22NW GP, as the general partner of 22NW Fund, 22NW Inc., as the general partner of 22NW, and Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the 1,015,048 Shares owned directly by 22NW Fund.

     

    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares reported herein that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that are not directly owned by such Reporting Person.

    8

    CUSIP No. 590328209

     

    (b)Percent of class:

     

    The following percentages are based on 13,410,243 Shares outstanding as of November 1, 2022, which is the total number of Shares outstanding as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

     

    As of the close of business on December 31, 2022, each of 22NW Fund, 22NW, 22NW GP, 22NW Inc. and Mr. English may be deemed to beneficially own approximately 7.6% of the outstanding Shares.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2022.

    9

    CUSIP No. 590328209

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    10

    CUSIP No. 590328209

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2023 22NW FUND, LP
       
      By: 22NW Fund GP, LLC
    General Partner
       
      By: /s/ Aron R. English
        Name: Aron R. English
        Title: Manager

     

     

      22NW, LP
       
      By: 22NW GP, Inc.
    General Partner
       
      By: /s/ Aron R. English
        Name: Aron R. English
        Title: President and Sole Shareholder

     

     

      22NW FUND GP, LLC
       
      By: /s/ Aron R. English
        Name: Aron R. English
        Title: Manager

     

     

      22NW GP, INC.
       
      By: /s/ Aron R. English
        Name: Aron R. English
        Title: President and Sole Shareholder

     

     

      /s/ Aron R. English
      ARON R. ENGLISH

     

    11

     

     

    Get the next $MACK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACK
    Financials

    Live finance-specific insights

    See more
    • Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

      5/10/24 4:30:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

      5/9/24 7:30:00 AM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its stockholders, subject to receipt of stockholder approval of the Plan of Dissolution. The Company currently estimates a cash divid

      4/30/24 5:15:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      2/14/24 4:20:24 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      1/25/24 4:05:32 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      12/13/23 4:05:25 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

      5/10/24 4:30:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

      5/9/24 7:30:00 AM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/28/23 4:05:12 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/11/23 4:05:08 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      11/20/23 6:59:37 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/28/23 4:05:12 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/11/23 4:05:08 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      11/20/23 6:59:37 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • 180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

      MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv

      5/28/21 8:00:00 AM ET
      $MACK
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Merrimack Pharmaceuticals Inc.

      15-12G - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/20/24 4:05:28 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Merrimack Pharmaceuticals Inc.

      10-Q - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/15/24 4:15:28 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Merrimack Pharmaceuticals Inc.

      25 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/10/24 4:45:35 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care